Cryoport, Inc. — Q3 2023 Form 10-Q
Business context and reporting period
Quarter ended September 30, 2023; filed November 9, 2023. Cryoport provides temperature-controlled logistics, storage, processing and cryogenic systems to life-sciences markets. It reported one operating segment, serving more than 3,000 customers through 48 locations.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $56.2m | $60.5m | $176.0m | $176.9m |
| Gross margin | $24.3m; 43.2% | $26.4m; 43.7% | $76.1m; 43.2% | $77.6m; 43.9% |
| Operating loss | $(16.9)m | $(7.8)m | $(45.3)m | $(20.9)m |
| Net loss | $(13.3)m | $(5.3)m | $(37.2)m | $(27.9)m |
| Net loss attributable to common stockholders | $(15.3)m | $(7.3)m | $(43.2)m | $(33.9)m |
| Adjusted EBITDA (non-GAAP) | $(3.1)m | $4.7m | $(1.7)m | $13.0m |
| Operating cash flow | — | $(3.2)m | $(5.5)m |
Q3 service revenue rose 8.2% to $36.0m, while product revenue fell 25.9% to $20.1m. For the nine-month period, service revenue grew 6.2% to $107.1m and product revenue declined 9.5% to $68.9m. The nine-month common-stockholder loss was $0.89 per share, versus $0.69 a year earlier.
At September 30, cash and cash equivalents were $59.5m and short-term investments were $406.4m, for total liquid resources of $465.9m. Working capital was $504.2m. Total assets were $1.001bn and total liabilities were $463.1m. Convertible notes had a net carrying value of $378.0m: $14.3m principal due 2025 and $371.2m due 2026. Cash, cash equivalents and short-term investments were $523.3m at December 31, 2022.
Nine-month investing cash flow was $50.8m, including $82.5m in investment maturities and $27.2m of property and equipment purchases. Financing cash flow was $(23.7)m, primarily reflecting the $25.0m note repurchase. The filing reports liquidity and management expects current cash, investments and projected cash flows to meet operating and capital needs for at least 12 months; it also says additional capital may be needed before sustained profitability.
Material changes versus prior comparable period
- Q3 revenue declined 7.1%; nine-month revenue was down 0.5%. Q3 biopharma/pharma revenue fell 3.3%, animal health fell 28.5%, and reproductive medicine was nearly flat.
- Management attributed product weakness particularly to lower cryogenic-system demand in China; animal-health results reflected weaker breeder demand. Service growth included bioservices and support for commercial cell and gene therapies.
- Nine-month SG&A increased 23.6% to $108.1m, and engineering and development costs rose 20.3% to $13.3m. Management cited infrastructure and competency investment, higher payroll, facilities, stock compensation, depreciation and acquisition/integration costs.
- Nine-month adjusted EBITDA moved from $13.0m positive to a $1.7m loss. Gross margin declined year over year, including lower product margin, which management linked partly to inflationary manufacturing costs and safety-stock buildup.
- Cash and investments decreased $57.5m from year-end 2022. The company used $3.2m in operating cash, though less than the $5.5m used in the prior-year period.
Outlook, commentary, risks and unusual items
- No specific full-year revenue or earnings guidance is provided. Management expects continued near-term operating losses while investing in supply-chain initiatives, geographic expansion and technology.
- The company supported 670 clinical trials, including 81 in Phase 3, and 12 commercial therapies. Management views trial progression and commercialization as potential future growth drivers, while noting clinical-trial start delays and slower client ramps.
- Two IntegriCell centers of excellence, in Houston and Liège, were expected to be operational and ready for validation in Q2 2024. In November 2023, after quarter-end, Cryoport completed the approximately $3.1m acquisition of Tec4med, a supply-chain monitoring and visibility provider.
- In September, Cryoport repurchased $31.3m principal amount of its 2026 notes for $25.0m cash, recording a $5.7m gain on extinguishment. The gain benefited reported earnings but is not recurring operating revenue.
- The 2022 New Prague fire had an estimated $9.4m revenue impact, primarily in Q1 2022. The company had received $15.1m of insurance proceeds by September 2023 and recognized a $2.6m insurance-related gain in the first nine months of 2023.
- Key exposures include demand weakness, clinical-trial timing, inflation and supply-chain constraints, foreign-exchange movements, geopolitical disruption including the Russia-Ukraine conflict, and potential goodwill or intangible-asset impairment. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
- Management stated that unrealized losses on certain available-for-sale debt securities were primarily interest-rate related and not considered credit losses; it did not intend, nor expect to be required, to sell them before recovery of amortized cost.
Important facts for investors to verify
- Whether service growth and clinical-trial/commercial therapy activity can offset continued product weakness, particularly in China and animal health.
- Whether expense growth moderates and the company can improve operating performance and adjusted EBITDA without materially reducing planned investments.
- Cash and investment levels, capital spending, operating cash use, and management’s 12-month liquidity assumptions.
- Convertible-note terms, remaining principal and future debt obligations; assess the one-time benefit from the 2026 note repurchase separately.
- Execution and costs of the IntegriCell centers and Tec4med integration, alongside acquisition-related commitments and contingent consideration.
- Potential effects of foreign exchange, interest rates, supply-chain disruption and impairment assumptions on reported results and asset values.